399 related articles for article (PubMed ID: 33727066)
1. Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects.
Al-Kuraishy HM; Al-Gareeb AI; Qusty N; Cruz-Martins N; El-Saber Batiha G
Pulm Pharmacol Ther; 2021 Apr; 67():102008. PubMed ID: 33727066
[TBL] [Abstract][Full Text] [Related]
2. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
3. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
4. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
Vitiello A; Ferrara F
Respir Med; 2021 Mar; 178():106322. PubMed ID: 33550151
[TBL] [Abstract][Full Text] [Related]
5. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.
Deftereos SG; Giannopoulos G; Vrachatis DA; Siasos GD; Giotaki SG; Gargalianos P; Metallidis S; Sianos G; Baltagiannis S; Panagopoulos P; Dolianitis K; Randou E; Syrigos K; Kotanidou A; Koulouris NG; Milionis H; Sipsas N; Gogos C; Tsoukalas G; Olympios CD; Tsagalou E; Migdalis I; Gerakari S; Angelidis C; Alexopoulos D; Davlouros P; Hahalis G; Kanonidis I; Katritsis D; Kolettis T; Manolis AS; Michalis L; Naka KK; Pyrgakis VN; Toutouzas KP; Triposkiadis F; Tsioufis K; Vavouranakis E; Martinèz-Dolz L; Reimers B; Stefanini GG; Cleman M; Goudevenos J; Tsiodras S; Tousoulis D; Iliodromitis E; Mehran R; Dangas G; Stefanadis C;
JAMA Netw Open; 2020 Jun; 3(6):e2013136. PubMed ID: 32579195
[TBL] [Abstract][Full Text] [Related]
6. [Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of novel coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT)].
Mareev VY; Orlova YA; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Plisyk AG; Seredenina EM; Potapenko AV; Malakhov PS; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Asratyan DA; Zhdanova EA; Mareev YV; Begrambekova YL; Shatochina EA; Kamalov АА
Kardiologiia; 2020 Oct; 60(9):4-21. PubMed ID: 33131470
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia.
Pinzón MA; Cardona Arango D; Betancur JF; Ortiz S; Holguín H; Arias Arias C; Muñoz Palacio BJ; Amarillo M; Llano JF; Montoya P
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):66. PubMed ID: 34521428
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial.
Rahman M; Datta PK; Islam K; Haque M; Mahmud R; Mallik U; Hasan P; Haque M; Faruq I; Sharif M; Ratul RH; Azad KAK; Miah T; Rahman MM
PLoS One; 2022; 17(11):e0277790. PubMed ID: 36383611
[TBL] [Abstract][Full Text] [Related]
12. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
13. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
Mareev VY; Orlova YA; Plisyk AG; Pavlikova EP; Akopyan ZA; Matskeplishvili ST; Malakhov PS; Krasnova TN; Seredenina EM; Potapenko AV; Agapov MA; Asratyan DA; Dyachuk LI; Samokhodskaya LM; Mershina ЕА; Sinitsyn VE; Pakhomov PV; Zhdanova EA; Mareev YV; Begrambekova YL; Kamalov АА
Kardiologiia; 2021 Mar; 61(2):15-27. PubMed ID: 33734043
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.
Solerte SB; Di Sabatino A; Galli M; Fiorina P
Acta Diabetol; 2020 Jul; 57(7):779-783. PubMed ID: 32506195
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
16. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
[TBL] [Abstract][Full Text] [Related]
17. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review.
Nas K; Eryilmaz N; Geyik MF; Altaş A
Rheumatol Int; 2021 Apr; 41(4):811-817. PubMed ID: 33611657
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
20. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
